D-Wave Quantum vs. Rigetti Computing: Which Cutting Edge Quantum Stock Is a Better Buy in 2026?

D-Wave reported FY 2025 revenue of about $24.6 million, up approximately 180%, while Rigetti generated about $7.1 million, down more than 34%; both reported substantial net losses. D-Wave cited expanding commercial deployments and a sales pipeline up more than 120% since year-end, while Rigetti has a potential government award of up to $100 million over three years. Both stocks have very high price-to-sales ratios and substantial execution risks; the article favors Rigetti for investors seeking long-term upside.

Analysis

The key distinction is monetization proof versus technology optionality—not which balance sheet looks cleaner. D-Wave’s deployment signals could create a recurring QCaaS flywheel, but customer logos and pipeline growth have little valuation value until they convert into disclosed, repeatable revenue. Watch bookings-to-revenue conversion, customer concentration, and gross margin; absent those, its growth rate can coexist with continued dilution and multiple compression. Rigetti’s prospective government support may reduce near-term technical funding risk, but an award tied to milestones and government equity is not equivalent to committed, non-dilutive commercial demand. It may also entrench dependence on public-sector budgets while multiyear processor development delays commercial proof.

Near term, expect headline-driven volatility in both; neither reported cash generation nor current valuation provides a reliable floor. Over 1–3 months, D-Wave’s next disclosures on paid deployments and pipeline conversion are the cleaner commercial catalyst; for Rigetti, verify award terms, milestones, cash proceeds, and equity dilution. Over 6–18 months, the decisive test is whether either platform produces repeatable customer economics rather than pilots or R&D progress. The contrarian angle: the bullish case for Rigetti may overweight technical promise and government backing, while the market may underweight D-Wave’s commercial lead—but that lead is not yet proven economically. The thesis fails if D-Wave’s deployments do not translate into accelerating recognized revenue, or if Rigetti secures funded milestones and demonstrates repeatable commercial sales.

Key Decisions for Investors

• Avoid treating either name as a core holding; at most, use a small, explicitly speculative allocation. The supplied figures do not establish durable unit economics, and extreme sales multiples leave both exposed to financing and expectation resets.
• For a relative-value expression, consider a small long QBTS / short RGTI pair, sized for high volatility rather than valuation convergence. The bet is on commercial conversion outrunning technical optionality, not on quantum adoption broadly. Set a thesis stop if D-Wave deployment growth fails to lift reported revenue or if Rigetti converts government support into funded milestones and commercial traction; short squeezes and event gaps can overwhelm the spread.
• Before adding to QBTS, require evidence in reported revenue, paid recurring usage, and customer concentration—not pipeline or named deployments alone. A miss on conversion is a reason to exit the relative long.
• Treat RGTI’s potential award as an alert, not a buy signal until award conditions, cash timing, government equity terms, and dilution are verified. Stronger-than-expected funded milestones or customer sales would invalidate the short leg.